Create a narrative

Avadel Pharmaceuticals Community

NasdaqGM:AVDL Community

1 Narratives written by author
0 Comments on narratives written by author
18 Fair Values set on narratives written by author

Avadel Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

New Indications And Patient Focus Will Deliver Long-Term Market Strength

Key Takeaways Strong demand for LUMRYZ and favorable legal outcomes position Avadel for sustained growth and expanded market opportunities in sleep disorders. Enhanced patient engagement, robust IP protection, and strategic investments support premium pricing, improved profitability, and long-term competitive strength.

US$18.00

FV

23.5% undervalued

24.96%

Revenue growth p.a.

0

0

10

Updated